Ad5-nCoV Vaccine


Research Institution



Ad5-nCoV is the first novel coronavirus vaccine for COVID-19 in a Phase 1 Clinical Trial in China. The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform.

The Ad5-nCoV vaccine candidate is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein.

Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate can induce a strong immune response in animal models. Preclinical animal safety studies also demonstrated a good safety profile.

Research Team


Project Details

Funding Sources

Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital

Project Phases

Planned Time to Trials

Trials Active

Additional Resources

  • April 9, 2020 - CanSino Biologics Inc. Chairman Xuefeng YU filed a public statement which says 'Based on the preliminary safety data of the phase I clinical trial for the Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Type 5 Vector) (the “Ad5-nCoV”), the Company and the Institute of Biotechnology, Academy of Military Medical Sciences plan to initiate phase II clinical trial for Ad5-nCoV in China ..... soon.
  • March 17, 2020 - CanSinoBIO’s Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China.


Hover for more information.
No items found.

Get In Touch

Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.